loading
Schlusskurs vom Vortag:
$1.08
Offen:
$1.06
24-Stunden-Volumen:
38,075
Relative Volume:
0.05
Marktkapitalisierung:
$36.93M
Einnahmen:
$3.04M
Nettoeinkommen (Verlust:
$-33.97M
KGV:
-0.8126
EPS:
-1.33
Netto-Cashflow:
$-52.47M
1W Leistung:
-1.36%
1M Leistung:
-10.33%
6M Leistung:
-55.35%
1J Leistung:
-84.83%
1-Tages-Spanne:
Value
$1.06
$1.0994
1-Wochen-Bereich:
Value
$1.05
$1.13
52-Wochen-Spanne:
Value
$1.02
$7.88

Rani Therapeutics Holdings Inc Stock (RANI) Company Profile

Name
Firmenname
Rani Therapeutics Holdings Inc
Name
Telefon
(408) 457-3700
Name
Adresse
2051 RINGWOOD AVENUE, SAN JOSE
Name
Mitarbeiter
106
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-31
Name
Neueste SEC-Einreichungen
Name
RANI's Discussions on Twitter

Vergleichen Sie RANI mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RANI
Rani Therapeutics Holdings Inc
1.085 36.93M 3.04M -33.97M -52.47M -1.33
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.48 127.64B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.03 65.95B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
656.04 37.92B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.19 32.98B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.08 26.89B 3.81B -644.79M -669.77M -6.24

Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-02 Eingeleitet Oppenheimer Outperform
2024-06-14 Eingeleitet Maxim Group Buy
2024-06-13 Eingeleitet Rodman & Renshaw Buy
2023-04-17 Fortgesetzt BTIG Research Buy
2022-10-11 Eingeleitet UBS Buy
2022-07-27 Eingeleitet H.C. Wainwright Buy
2022-06-13 Eingeleitet Wedbush Outperform
Alle ansehen

Rani Therapeutics Holdings Inc Aktie (RANI) Neueste Nachrichten

pulisher
May 03, 2025

Rani Therapeutics (RANI) Expected to Announce Quarterly Earnings on Monday - Defense World

May 03, 2025
pulisher
Apr 30, 2025

Rani Therapeutics Board Restructures After DeBuono’s Retirement - TipRanks

Apr 30, 2025
pulisher
Apr 28, 2025

Ratio Examination: Rani Therapeutics Holdings Inc (RANI)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX

Apr 28, 2025
pulisher
Apr 28, 2025

Daily Progress: XPLR Infrastructure LP (XIFR) Drop -1.51, Closing at 8.46 - DWinneX

Apr 28, 2025
pulisher
Apr 28, 2025

Market Recap: PowerFleet Inc (AIOT)’s Negative Momentum, Closing at 5.12 - DWinneX

Apr 28, 2025
pulisher
Apr 28, 2025

Market Highlights: Clear Channel Outdoor Holdings Inc (CCO) Ends on a Low Note at 1.02 - DWinneX

Apr 28, 2025
pulisher
Apr 28, 2025

Post-Trade Analysis: Baytex Energy Corp (BTE) Climbs 0.61, Closing at 1.65 - DWinneX

Apr 28, 2025
pulisher
Apr 27, 2025

Brokerages Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Target Price at $12.33 - Defense World

Apr 27, 2025
pulisher
Apr 16, 2025

SEC Form DEFA14A filed by Rani Therapeutics Holdings Inc. - Quantisnow

Apr 16, 2025
pulisher
Apr 05, 2025

HC Wainwright Reaffirms “Buy” Rating for Rani Therapeutics (NASDAQ:RANI) - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

What is Zacks Small Cap’s Forecast for RANI FY2025 Earnings? - Defense World

Apr 04, 2025
pulisher
Apr 02, 2025

Rani Therapeutics stock hits 52-week low at $1.24 - Investing.com Australia

Apr 02, 2025
pulisher
Apr 02, 2025

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $12.33 Consensus PT from Analysts - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Rani Therapeutics Earnings Call: Tech Gains Amid Financial Strains - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

BTIG maintains Buy on Rani Therapeutics stock, $14 target - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

RANI: 2024 Financial Results - Yahoo Finance

Apr 01, 2025
pulisher
Apr 01, 2025

Stifel maintains Buy on Rani Therapeutics, $8 target By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

Stifel maintains Buy on Rani Therapeutics, $8 target - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2024 Earnings Call Transcript - Insider Monkey

Apr 01, 2025
pulisher
Apr 01, 2025

BTIG maintains Buy on Rani Therapeutics stock, $14 target By Investing.com - Investing.com UK

Apr 01, 2025
pulisher
Apr 01, 2025

Virtu Financial LLC Invests $62,000 in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) - Defense World

Apr 01, 2025
pulisher
Apr 01, 2025

Rani Therapeutics Reports 2024 Financial Results and Updates - TipRanks

Apr 01, 2025
pulisher
Mar 31, 2025

Earnings call transcript: Rani Therapeutics sees stock drop despite narrowing losses in Q4 2024 - Investing.com Canada

Mar 31, 2025
pulisher
Mar 31, 2025

Earnings call transcript: Rani Therapeutics sees stock drop despite narrowing losses in Q4 2024 By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Rani Therapeutics Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update - GlobeNewswire

Mar 31, 2025
pulisher
Mar 31, 2025

Breakthrough: Rani's Oral GLP-1 Shows 111% Bioequivalence in Latest Financial Report - Stock Titan

Mar 31, 2025
pulisher
Mar 28, 2025

Rani Therapeutics Holdings Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

An Overview of Rani Therapeutics Hldgs's Earnings - Benzinga

Mar 28, 2025
pulisher
Mar 27, 2025

Stifel maintains Buy on Rani Therapeutics stock, $8 target By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Stifel maintains Buy on Rani Therapeutics stock, $8 target - Investing.com India

Mar 27, 2025
pulisher
Mar 26, 2025

Rani Therapeutics stock holds buy rating, $14 target from BTIG By Investing.com - Investing.com Canada

Mar 26, 2025
pulisher
Mar 26, 2025

Rani Therapeutics reports oral drug matches injectable in obesity study By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Rani Therapeutics reports oral drug matches injectable in obesity study - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence Of RT-114, A GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally Via The RaniPill Capsule, To Subcutaneously Administered PG-102 - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Rani Therapeutics Announces Preclinical Data Demonstrating - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

Rani Therapeutics (RANI) Announces Preclinical Data Demonstrating Bioequivalence of RT-114 - StreetInsider.com

Mar 26, 2025
pulisher
Mar 26, 2025

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102 - Nasdaq

Mar 26, 2025
pulisher
Mar 26, 2025

Rani Therapeutics stock holds buy rating, $14 target from BTIG - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Game-Changing Oral GLP-1 Matches Injectable Performance: New Data Reveals 111% Bioavailability - Stock Titan

Mar 26, 2025
pulisher
Mar 25, 2025

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Mar 25, 2025
pulisher
Mar 25, 2025

Oral Biologics Pioneer Rani Therapeutics Announces 2024 Year-End Earnings Date - Stock Titan

Mar 25, 2025
pulisher
Mar 17, 2025

Rani Therapeutics (RANI) Expected to Announce Earnings on Wednesday - Armenian Reporter

Mar 17, 2025
pulisher
Mar 13, 2025

Head to Head Survey: Rani Therapeutics (NASDAQ:RANI) vs. CalciMedica (NASDAQ:CALC) - The AM Reporter

Mar 13, 2025
pulisher
Mar 12, 2025

Rani Therapeutics (RANI) Expected to Announce Quarterly Earnings on Wednesday - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Rani Therapeutics (NASDAQ:RANI) versus CalciMedica (NASDAQ:CALC) Financial Contrast - Defense World

Mar 11, 2025
pulisher
Mar 08, 2025

Brokerages Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Price Target at $12.33 - Defense World

Mar 08, 2025
pulisher
Mar 01, 2025

Canaccord Genuity Group Reaffirms “Buy” Rating for Rani Therapeutics (NASDAQ:RANI) - The AM Reporter

Mar 01, 2025
pulisher
Mar 01, 2025

Rani Therapeutics’ (RANI) Buy Rating Reiterated at Canaccord Genuity Group - Defense World

Mar 01, 2025
pulisher
Feb 27, 2025

Canaccord Genuity Group Reiterates Buy Rating for Rani Therapeutics (NASDAQ:RANI) - MarketBeat

Feb 27, 2025
pulisher
Feb 18, 2025

RANI: Impressive Bioavailability for RT-116 - Yahoo Finance

Feb 18, 2025

Finanzdaten der Rani Therapeutics Holdings Inc-Aktie (RANI)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Rani Therapeutics Holdings Inc-Aktie (RANI) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Imran Talat
Chief Executive Officer
Dec 09 '24
Buy
1.94
10,296
19,974
494,751
South Cone Investments Limited
10% Owner
Oct 15 '24
Sale
2.65
3,829,360
10,141,674
8,302,194
$72.41
price up icon 0.35%
$21.57
price up icon 0.24%
$32.80
price down icon 0.36%
$28.12
price up icon 0.99%
$101.25
price down icon 3.64%
biotechnology ONC
$254.09
price down icon 0.59%
Kapitalisierung:     |  Volumen (24h):